Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...
The typical cost of developing new medications may not be as high as generally believed, with a few ultra-costly medications skewing public discussions about the cost of pharmaceutical research and ...
A new report indicates that U.S. drugmakers will raise prices on at least 350 medications despite pressure from President ...
Please provide your email address to receive an email when new articles are posted on . The FDA issued draft guidance that would streamline testing of biosimilars. A separate plan would eliminate ...
Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug ...
The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...
HHS Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, MD, and CMS Administrator Mehmet Oz, MD, announced new FDA guidance aimed at making biosimilar drug development faster and less ...
Forbes contributors publish independent expert analyses and insights. Gil Press writes about technology, entrepreneurs and innovation. Will AI transform the typical trials and tribulations of drug ...
Competition to create new brand-name drugs is a key driver of innovation in the United States. Unfortunately, it also drives the relentless growth of healthcare spending. That’s because development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback